| review article | Q7318358 |
| scholarly article | Q13442814 |
| meta-analysis | Q815382 |
| systematic review | Q1504425 |
| P6179 | Dimensions Publication ID | 1011167965 |
| P356 | DOI | 10.1186/1471-2474-15-26 |
| P932 | PMC publication ID | 3903562 |
| P698 | PubMed publication ID | 24444034 |
| P5875 | ResearchGate publication ID | 259824834 |
| P50 | author | Matthew Richard Cawson | Q87130491 |
| P2093 | author name string | Chris Knight | |
| Dean Spurden | |||
| Alex Bird | |||
| Michelle Elaine Orme | |||
| Henry Wildey | |||
| Stephen Andrew Mitchell | |||
| P2860 | cites work | Clinical outcomes in psoriatic arthritis: A systematic literature review | Q26995307 |
| Indirect comparisons of competing interventions | Q28183606 | ||
| Combination of direct and indirect evidence in mixed treatment comparisons | Q29619499 | ||
| The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials | Q29619501 | ||
| Simultaneous comparison of multiple treatments: combining direct and indirect evidence. | Q34081552 | ||
| Assessment of risk of psoriatic arthritis in patients with plaque psoriasis: a systematic review of the literature | Q34113718 | ||
| Bayesian methods in meta-analysis and evidence synthesis | Q34329700 | ||
| Safety and efficacy of adalimumab in treatment of patients with psoriatic arthritis who had failed disease modifying antirheumatic drug therapy | Q34578832 | ||
| Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial | Q35555905 | ||
| Infliximab plus methotrexate is superior to methotrexate alone in the treatment of psoriatic arthritis in methotrexate-naive patients: the RESPOND study. | Q35819025 | ||
| Bayesian methods for evidence synthesis in cost-effectiveness analysis | Q36381197 | ||
| The psoriatic arthritis cost evaluation study: a cost-of-illness study on tumour necrosis factor inhibitors in psoriatic arthritis patients with inadequate response to conventional therapy. | Q36940942 | ||
| Risks and benefits of tumor necrosis factor-alpha inhibitors in the management of psoriatic arthritis: systematic review and metaanalysis of randomized controlled trials. | Q37125494 | ||
| A prospective, randomised, placebo-controlled study to identify biomarkers associated with active treatment in psoriatic arthritis: effects of adalimumab treatment on synovial tissue | Q37245184 | ||
| Use of indirect and mixed treatment comparisons for technology assessment | Q37259556 | ||
| Treatment recommendations for psoriatic arthritis. | Q37284516 | ||
| Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis: a systematic review and economic evaluation. | Q37844721 | ||
| Modelling the cost-effectiveness of biologic treatments for psoriatic arthritis | Q37920950 | ||
| European League Against Rheumatism recommendations for the management of psoriatic arthritis with pharmacological therapies | Q37939700 | ||
| Efficacy and safety of DMARDs in psoriatic arthritis: a systematic review | Q37984665 | ||
| Infliximab monotherapy in Japanese patients with moderate-to-severe plaque psoriasis and psoriatic arthritis. A randomized, double-blind, placebo-controlled multicenter trial | Q39284503 | ||
| Efficacy and tolerability of anti-tumour necrosis factor therapy in psoriatic arthritis patients: results from the South Swedish Arthritis Treatment Group register | Q42516230 | ||
| Cost-effectiveness analysis of a psoriasis care instruction programme with dithranol compared with UVB phototherapy and inpatient dithranol treatment | Q44122721 | ||
| Psoriatic arthritis (PA): a clinical, immunological and radiological study of 180 patients | Q44300565 | ||
| Golimumab, a new human tumor necrosis factor alpha antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: Twenty-four-week efficacy and safety results of a randomized, placebo-controlled study | Q46297341 | ||
| The development of candidate composite disease activity and responder indices for psoriatic arthritis (GRACE project) | Q47381622 | ||
| Patients with psoriatic arthritis have worse quality of life than those with psoriasis alone | Q48522893 | ||
| Modeling the progression of rheumatoid arthritis: a two-country model to estimate costs and consequences of rheumatoid arthritis. | Q50708359 | ||
| Cost effectiveness of golimumab for the treatment of active psoriatic arthritis. | Q51166513 | ||
| Development of composite measures for psoriatic arthritis: a report from the GRAPPA 2010 annual meeting. | Q51177636 | ||
| Comparison of two etanercept regimens for treatment of psoriasis and psoriatic arthritis: PRESTA randomised double blind multicentre trial. | Q52905765 | ||
| Indirect comparison of etanercept, infliximab, and adalumimab for psoriatic arthritis: mixed treatment comparison using placebo as common comparator | Q60701722 | ||
| Psoriatic arthritis (PSA)--an analysis of 220 patients | Q69409096 | ||
| Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial | Q74265787 | ||
| Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression | Q80330608 | ||
| Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial | Q81300604 | ||
| Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT) | Q81629371 | ||
| Life-table analysis of etanercept with or without methotrexate in patients with psoriatic arthritis | Q82294488 | ||
| Psoriatic arthritis | Q83154492 | ||
| Etanercept plus ciclosporin versus etanercept plus methotrexate for maintaining clinical control over psoriatic arthritis: a randomised pilot study | Q84973309 | ||
| P275 | copyright license | Creative Commons Attribution 2.0 Generic | Q19125117 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | psoriatic arthritis | Q511097 |
| anti-inflammatory agent | Q581996 | ||
| biological products | Q67008917 | ||
| P5008 | on focus list of Wikimedia project | ScienceSource | Q55439927 |
| P304 | page(s) | 26 | |
| P577 | publication date | 2014-01-20 | |
| P1433 | published in | BMC Musculoskeletal Disorders | Q15751716 |
| P1476 | title | Systematic review, network meta-analysis and economic evaluation of biological therapy for the management of active psoriatic arthritis | |
| P478 | volume | 15 |
| Q55109332 | Assessing the effectiveness of synthetic and biologic disease-modifying antirheumatic drugs in psoriatic arthritis - a systematic review. |
| Q38668352 | Comparative Risk of Harm Associated With the Use of Targeted Immunomodulators: A Systematic Review. |
| Q90288921 | Cost-Effectiveness Analysis of Sequential Biologic Therapy with Ixekizumab Versus Secukinumab in the Treatment of Active Psoriatic Arthritis with Concomitant Moderate-to-Severe Psoriasis in the UK |
| Q92137651 | Cost-Effectiveness of Secukinumab Versus Other Biologics in the Treatment of Psoriatic Arthritis: An Argentinean Perspective |
| Q49850238 | Cost-effectiveness analysis of secukinumab for the treatment of active psoriatic arthritis: a Canadian perspective |
| Q59337044 | Cost-effectiveness analysis of secukinumab versus other biologics and apremilast in the treatment of active Psoriatic arthritis: a Finnish perspective |
| Q51289760 | Cost-efficacy of biologic therapies for psoriatic arthritis from the perspective of the Taiwanese healthcare system. |
| Q55452701 | Cost Effectiveness of Secukinumab for the Treatment of Active Psoriatic Arthritis in the UK. |
| Q38636348 | EQ-5D studies in musculoskeletal and connective tissue diseases in eight Central and Eastern European countries: a systematic literature review and meta-analysis. |
| Q47093829 | Economic Evaluation of Dupilumab for the Treatment of Moderate-to-Severe Atopic Dermatitis in Adults |
| Q37453027 | Economic Evaluation of Timely Versus Delayed Use of Tumor Necrosis Factor Inhibitors for Treatment of Psoriatic Arthritis in the US. |
| Q33840422 | Economic impact of biologic utilization patterns in patients with psoriatic arthritis |
| Q38230740 | Etanercept: a review of its use in autoimmune inflammatory diseases |
| Q92464630 | Network meta-analysis and cost per responder of targeted Immunomodulators in the treatment of active psoriatic arthritis |
| Q37515034 | Pharmacoeconomic burden in the treatment of psoriatic arthritis: from systematic reviews to real clinical practice studies. |
| Q38230695 | Proteomics focusing on immune markers in psoriatic arthritis. |
| Q47717769 | Risk of tuberculosis comparison in new users of antitumour necrosis factor-α and with existing disease-modifying antirheumatic drug therapy. |
| Q92277529 | Systemic Psoriasis Therapies and Comorbid Disease in Patients with Psoriasis: A Review of Potential Risks and Benefits |
| Q40942139 | The use of adalimumab, etanercept, golimumab and infliximab in rheumatic pathologies: variation between label dosage and real-world use. |
Search more.